color littl clariti miss
sale pre-announc ep ahead lower expens
sale yoy expect pre-announc
link ran sever pocket weak across portfolio adj gm
estimate adj opm y/i vs estimate
due combin vs estimate sg vs
estimate cost control adj ep vs our/street estimate
dissect miss time issu slow ramp
previous provid initi color result today call allow
much detail project delay underli factor
popseq studi emphas unpredict custom time
project delay dtc focu un-anticip
market soft extrem cautiou outlook await new product
offer custom non-high-throughput sequenc management call
combin typic custom time factor happen coincid
signific chang prior near-term view
continu believ ilmn issu due either wane enthusiasm
sequenc chang market dynam remain posit genom
market ilmn posit howev still cautiou near-term concern
visibl remain un-answ beyond easi comp catalyst re-invigor sale
growth obviou time valuat alreadi indic expect
solid rebound see potenti increment downsid project
time pace remain under-perform share look updat
ilmn product pipelin project pace shipments/util reassess
ep guid updat adjust estim
updat adj ep guid call initi
sale guid impli leav fy back-half ramp anoth pressur
point continu expect sale growth lower ep estim
see sale growth unchang adj ep
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart san diego california
consum servic genet analysi
compani proprietari product servic
use research broad spectrum
scientif activ gain greater understand
genet variat biolog function
tool play import role
develop creation molecular test
posit technolog
market posit overal genom
market see near-term risk tie execut
visibl custom time demand
pend acquisit macro
competit risk
price object base dcf analysi assum wacc
approxim termin growth rate po approxim
revenu estim roughli ep estim in-lin
year averag forward multipl consid justifi given near-term question
certain pocket busi relat execut
downsid risk po weaker-than-expect academ fund lower
consum pull-through competit within genet analysi market regulatori
reimburs uncertainti clinic sequenc market acquisit relat
integr issu grow concern data privaci slower-than-expect
uptak new product
upsid risk po strong recoveri instrument placement overal
sequenc demand new product cycl stabilization/recoveri direct-to-
consum dtc market increas spend high-throughput custom better
clinic reimbursement/market penetr acquisit compani
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
